Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y. Kastelein JJ, et al. Lancet. 2015 May 30;385(9983):2153-61. doi: 10.1016/S0140-6736(14)62115-2. Epub 2015 Mar 3. Lancet. 2015. PMID: 25743173 Clinical Trial.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY; ENSURE-AF investigators. Goette A, et al. Lancet. 2016 Oct 22;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. Epub 2016 Aug 30. Lancet. 2016. PMID: 27590218 Clinical Trial.
Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
Lip GYH, Al-Saady N, Jin J, Sun M, Melino M, Winters SM, Zamoryakhin D, Goette A. Lip GYH, et al. Among authors: al saady n. Am J Cardiol. 2017 Sep 1;120(5):792-796. doi: 10.1016/j.amjcard.2017.06.005. Epub 2017 Jun 15. Am J Cardiol. 2017. PMID: 28709650 Free article. Clinical Trial.
Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M, Al-Saady N, Hjortshøj SP, Goudev A, Huber K, Cohen A, Jin J, Melino M, Winters SM, Goette A, Lip GYH. Kozieł M, et al. Among authors: al saady n. Clin Res Cardiol. 2020 Aug;109(8):1018-1024. doi: 10.1007/s00392-019-01594-9. Epub 2020 Jan 8. Clin Res Cardiol. 2020. PMID: 31915996 Free PMC article. Clinical Trial.
Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) randomized trial.
Lip GYH, Merino JL, Banach M, Al-Saady N, Jin J, Melino M, Winters SM, Kozieł M, Goette A. Lip GYH, et al. Among authors: al saady n. J Arrhythm. 2020 Apr 15;36(3):430-438. doi: 10.1002/joa3.12341. eCollection 2020 Jun. J Arrhythm. 2020. PMID: 32528568 Free PMC article.
Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study.
Berlin S, Goette A, Summo L, Lossie J, Gebauer A, Al-Saady N, Calo L, Naccarelli G, Schunck WH, Fischer R, Camm AJ, Dobrev D. Berlin S, et al. Among authors: al saady n. Int J Cardiol Heart Vasc. 2020 Jul 10;29:100573. doi: 10.1016/j.ijcha.2020.100573. eCollection 2020 Aug. Int J Cardiol Heart Vasc. 2020. PMID: 32685659 Free PMC article.
43 results